Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)

M. P. De Vetten; J. H. Jansen; B. A. Van Der Reijden; M. S. Berger; J. M.J.M. Zijlmans; B. Löwenberg

doi:10.1046/j.1365-2141.2000.02402.x

Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)

M. P. De Vetten, J. H. Jansen, B. A. Van Der Reijden, M. S. Berger, J. M.J.M. Zijlmans, B. Löwenberg

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

The anti-CD33 monoclonal antibody linked to NAc-gamma calicheamicin gemtuzumab ozogamicin (CMA-676) was used to treat a patient with Philadelphia/bcr-abl-positive acute myeloid leukaemia. We report a morphological and cytogenetic complete remission after treatment with two doses of gemtuzumab ozogamicin as a single agent. Using real-time polymerase chain reaction (PCR), gemtuzumab ozogamicin treatment resulted in a 3-1og tumour mass reduction in bone marrow.

Original language	English (US)
Pages (from-to)	277-279
Number of pages	3
Journal	British Journal of Haematology
Volume	111
Issue number	1
DOIs	https://doi.org/10.1046/j.1365-2141.2000.02402.x
State	Published - 2000
Externally published	Yes

Keywords

Acute myeloid leukaemia
Gemtuzumab ozogamicin (CMA-676)

ASJC Scopus subject areas

Hematology

Access to Document

10.1046/j.1365-2141.2000.02402.x

Cite this

De Vetten, M. P., Jansen, J. H., Van Der Reijden, B. A., Berger, M. S., Zijlmans, J. M. J. M., & Löwenberg, B. (2000). Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676). British Journal of Haematology, 111(1), 277-279. https://doi.org/10.1046/j.1365-2141.2000.02402.x

De Vetten, MP, Jansen, JH, Van Der Reijden, BA, Berger, MS, Zijlmans, JMJM & Löwenberg, B 2000, 'Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)', British Journal of Haematology, vol. 111, no. 1, pp. 277-279. https://doi.org/10.1046/j.1365-2141.2000.02402.x

@article{fbd7889204e74cd68290f6cf1f61ce87,

title = "Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)",

abstract = "The anti-CD33 monoclonal antibody linked to NAc-gamma calicheamicin gemtuzumab ozogamicin (CMA-676) was used to treat a patient with Philadelphia/bcr-abl-positive acute myeloid leukaemia. We report a morphological and cytogenetic complete remission after treatment with two doses of gemtuzumab ozogamicin as a single agent. Using real-time polymerase chain reaction (PCR), gemtuzumab ozogamicin treatment resulted in a 3-1og tumour mass reduction in bone marrow.",

keywords = "Acute myeloid leukaemia, Gemtuzumab ozogamicin (CMA-676)",

author = "{De Vetten}, {M. P.} and Jansen, {J. H.} and {Van Der Reijden}, {B. A.} and Berger, {M. S.} and Zijlmans, {J. M.J.M.} and B. L{\"o}wenberg",

year = "2000",

doi = "10.1046/j.1365-2141.2000.02402.x",

language = "English (US)",

volume = "111",

pages = "277--279",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)

AU - De Vetten, M. P.

AU - Jansen, J. H.

AU - Van Der Reijden, B. A.

AU - Berger, M. S.

AU - Zijlmans, J. M.J.M.

AU - Löwenberg, B.

PY - 2000

Y1 - 2000

N2 - The anti-CD33 monoclonal antibody linked to NAc-gamma calicheamicin gemtuzumab ozogamicin (CMA-676) was used to treat a patient with Philadelphia/bcr-abl-positive acute myeloid leukaemia. We report a morphological and cytogenetic complete remission after treatment with two doses of gemtuzumab ozogamicin as a single agent. Using real-time polymerase chain reaction (PCR), gemtuzumab ozogamicin treatment resulted in a 3-1og tumour mass reduction in bone marrow.

AB - The anti-CD33 monoclonal antibody linked to NAc-gamma calicheamicin gemtuzumab ozogamicin (CMA-676) was used to treat a patient with Philadelphia/bcr-abl-positive acute myeloid leukaemia. We report a morphological and cytogenetic complete remission after treatment with two doses of gemtuzumab ozogamicin as a single agent. Using real-time polymerase chain reaction (PCR), gemtuzumab ozogamicin treatment resulted in a 3-1og tumour mass reduction in bone marrow.

KW - Acute myeloid leukaemia

KW - Gemtuzumab ozogamicin (CMA-676)

UR - http://www.scopus.com/inward/record.url?scp=0033764107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033764107&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2000.02402.x

DO - 10.1046/j.1365-2141.2000.02402.x

M3 - Article

C2 - 11091212

AN - SCOPUS:0033764107

SN - 0007-1048

VL - 111

SP - 277

EP - 279

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukaemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA-676)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this